Stockreport

Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference [Yahoo! Finance]

Kyverna Therapeutics, Inc.  (KYTX) 
PDF First patient enrolled in registrational Phase 3 trial in generalized myasthenia gravis (gMG) Completed follow-on offering extends cash runway into 2028, expected to [Read more]